Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1911 Target Snapshot

Succinate-semialdehyde dehydrogenase, mitochondrial · SINGLE PROTEIN · Homo sapiens

19Compounds
5Assays
0Approved Drugs
16.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Succinate-semialdehyde dehydrogenase, mitochondrial shows approved-linked disease relevance led by bipolar disorder. 5 more disease programs remain visible in the same review block. 3 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P51649. Start with bipolar disorder, then reuse UniProt P51649 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with bipolar disorder, then reuse UniProt P51649 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 3 linked drugs
Open source guide
Disease program
bipolar disorder

Succinate-semialdehyde dehydrogenase, mitochondrial shows approved-linked disease relevance led by bipolar disorder. 5 more disease programs remain visible in the same review block. 3 linked drugs remain visible in the same block.

Start review with bipolar disorder because it currently carries approved-linked support. Linked drugs include DIVALPROEX SODIUM, VALPROATE SODIUM, VALPROIC ACID. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 3 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Succinate-semialdehyde dehydrogenase, mitochondrial as ChEMBL target CHEMBL1911, mapped to UniProt P51649. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Succinate-semialdehyde dehydrogenase, mitochondrial
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1911
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P51649
Succinate-semialdehyde dehydrogenase, mitochondrial
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Succinate-semialdehyde dehydrogenase, mitochondrial is the right protein anchor across sources, using UniProt P51649 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why bipolar disorder is currently framed as approved-linked support. It currently carries 3 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSuccinate-semialdehyde dehydrogenase, mitochondrial
UniProt AccessionP51649
Component TypeProtein
Sequence Length535 aa

Succinate-semialdehyde dehydrogenase, mitochondrial

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Succinate-semialdehyde dehydrogenase, mitochondrial, mapped to UniProt P51649. Sequence length is 535 aa.

Mapped IDP51649
Review nameSuccinate-semialdehyde dehydrogenase, mitochondrial
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Succinate-semialdehyde dehydrogenase, mitochondrial shows approved-linked disease relevance led by bipolar disorder. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
bipolar disorder
3 linked drugs · 3 direct · 3 efficacy
Linked drugDIVALPROEX SODIUM
Linked drugVALPROATE SODIUM
Linked drugVALPROIC ACID
Approved-linked Approved
epilepsy
3 linked drugs · 3 direct · 3 efficacy
Linked drugDIVALPROEX SODIUM
Linked drugVALPROATE SODIUM
Linked drugVALPROIC ACID
Approved-linked Approved
migraine disorder
3 linked drugs · 3 direct · 3 efficacy
Linked drugDIVALPROEX SODIUM
Linked drugVALPROATE SODIUM
Linked drugVALPROIC ACID
Approved-linked Approved
Seizure
3 linked drugs · 3 direct · 3 efficacy
Linked drugDIVALPROEX SODIUM
Linked drugVALPROATE SODIUM
Linked drugVALPROIC ACID
Approved-linked Approved
bipolar I disorder
2 linked drugs · 2 direct · 2 efficacy
Linked drugDIVALPROEX SODIUM
Linked drugVALPROIC ACID
Approved-linked Approved
complex partial epilepsy
2 linked drugs · 2 direct · 2 efficacy
Linked drugDIVALPROEX SODIUM
Linked drugVALPROIC ACID
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with bipolar disorder because it currently carries approved-linked support. Linked drugs include DIVALPROEX SODIUM, VALPROATE SODIUM, VALPROIC ACID. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasebipolar disorder
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Assay Mix

Activity Type Distribution

IC5016.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL378577 6.46 IC50 350.0 Preclinical
CHEMBL13883 4.81 IC50 15600.0 Preclinical
CHEMBL14193 4.61 IC50 24700.0 Preclinical
CHEMBL378361 4.48 IC50 33100.0 Preclinical
Distribution

pChEMBL Value Distribution

0
5.0
0
5.5
1
6.0
0
6.5
0
7.0
0
7.5
0
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Assay Landscape

Assay Landscape

5
Total Assays
7
Tested Compounds
1
Assay Types
Binding — 5 assays, 7 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 5 7 5.1

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine